regardless of positive clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable resistance from managed care entities. The insurers are often building obstacles to reimbursement, including high expense requirements and prior authorization that restrict user access. … Read More